Brought to you by 
Ophthalmic start-up MacuSight raises $26mm with Series A
30 Oct 2006
Executive Summary
MacuSight (small molecules for eye diseases) grossed $8mm with the close of an additional tranche of its Series A financing, which included participation from returning investors. The company raised the initial $17.5mm in July 2004.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ophthalmic start-up MacuSight raises $26mm with Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice